Assessment of myeloid response and iron status among Sudanese pediatric ESKD on hemodialysis through reticulocyte parameters and β-globin mRNA expression.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
26 Oct 2024
Historique:
received: 17 12 2023
accepted: 08 10 2024
medline: 27 10 2024
pubmed: 27 10 2024
entrez: 27 10 2024
Statut: epublish

Résumé

Sudanese children with End-Stage Kidney Disease (ESKD) often show limited improvement in hemoglobin levels despite treatment with recombinant human erythropoietin (rHuEPO). This study aims to assess the response to rHuEPO therapy by analyzing β-globin mRNA expression and reticulocyte parameters. Additionally, it classifies anemia among Sudanese pediatric patients based on iron status, considering age and gender as biological markers for evaluating treatment response. A prospective observational cohort study was conducted from January 2019 to February 2020 in Khartoum, Sudan, involving 45 anemic children aged 2 to 15 years diagnosed with ESKD. The treatment protocol included rHuEPO injections and maintenance hemodialysis. Laboratory assessments consisted of complete blood count (CBC), absolute reticulocyte count, ferritin, and transferrin measurements. β-globin mRNA expression was quantified using reverse transcription polymerase chain reaction (RT-PCR), and reticulocyte parameters, including Reticulocyte Hemoglobin Content (CHr), percentage of hypochromic reticulocytes (HYPO%), and Immature Reticulocyte Fraction (IRF), were measured via flow cytometry. Significant variations in hemoglobin levels were observed across different age groups (p = 0.011). Gender analysis revealed a significant association with IRF, showing a lower IRF in male patients (p = 0.017). However, there were no significant differences in hemoglobin levels between genders (p = 0.999). β-globin mRNA expression showed considerable variability, with a strong positive correlation with hemoglobin levels (r = 0.875, p < 0.0001). Age and gender significantly influence treatment responses in children with ESKD, highlighting the need to consider growth physiology in anemia management. This study underscores the variability in β-globin mRNA expression and its association with Flow Cytometry parameters, demonstrating their effectiveness in evaluating iron status and guiding rHuEPO dosage.

Sections du résumé

BACKGROUND BACKGROUND
Sudanese children with End-Stage Kidney Disease (ESKD) often show limited improvement in hemoglobin levels despite treatment with recombinant human erythropoietin (rHuEPO). This study aims to assess the response to rHuEPO therapy by analyzing β-globin mRNA expression and reticulocyte parameters. Additionally, it classifies anemia among Sudanese pediatric patients based on iron status, considering age and gender as biological markers for evaluating treatment response.
METHODS METHODS
A prospective observational cohort study was conducted from January 2019 to February 2020 in Khartoum, Sudan, involving 45 anemic children aged 2 to 15 years diagnosed with ESKD. The treatment protocol included rHuEPO injections and maintenance hemodialysis. Laboratory assessments consisted of complete blood count (CBC), absolute reticulocyte count, ferritin, and transferrin measurements. β-globin mRNA expression was quantified using reverse transcription polymerase chain reaction (RT-PCR), and reticulocyte parameters, including Reticulocyte Hemoglobin Content (CHr), percentage of hypochromic reticulocytes (HYPO%), and Immature Reticulocyte Fraction (IRF), were measured via flow cytometry.
RESULTS RESULTS
Significant variations in hemoglobin levels were observed across different age groups (p = 0.011). Gender analysis revealed a significant association with IRF, showing a lower IRF in male patients (p = 0.017). However, there were no significant differences in hemoglobin levels between genders (p = 0.999). β-globin mRNA expression showed considerable variability, with a strong positive correlation with hemoglobin levels (r = 0.875, p < 0.0001).
CONCLUSION CONCLUSIONS
Age and gender significantly influence treatment responses in children with ESKD, highlighting the need to consider growth physiology in anemia management. This study underscores the variability in β-globin mRNA expression and its association with Flow Cytometry parameters, demonstrating their effectiveness in evaluating iron status and guiding rHuEPO dosage.

Identifiants

pubmed: 39462360
doi: 10.1186/s12882-024-03806-5
pii: 10.1186/s12882-024-03806-5
doi:

Substances chimiques

RNA, Messenger 0
beta-Globins 0
Erythropoietin 11096-26-7
Iron E1UOL152H7
Recombinant Proteins 0
Hemoglobins 0
Transferrin 0
Ferritins 9007-73-2

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

380

Informations de copyright

© 2024. The Author(s).

Références

Hussein R, Ye X, Ellidir R, Ali E, Bakhiet Y, Karar M, et al. # 4285 causes of pediatric end stage kidney disease in sudan. Nephrol Dial Transplant. 2023;38(Supplement_1):gfad063c_4285.
Wharton G, Ali OE, Khalil S, Yagoub H, Mossialos E. Rebuilding Sudan’s health system: opportunities and challenges. Lancet. 2020;395(10219):171–3.
doi: 10.1016/S0140-6736(19)32974-5 pubmed: 31954447
UNICEF Sudan. Consolidated Strategy Note for the Country Programme of Cooperation 2018–2021 in Sudan.
Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol. 2011;7(11):635–41.
doi: 10.1038/nrneph.2011.115 pubmed: 21894183 pmcid: 5739031
Chang CC, Kass L. Clinical significance of immature reticulocyte fraction determined by automated reticulocyte counting. Am J Clin Pathol. 1997;108(1):69–73.
doi: 10.1093/ajcp/108.1.69 pubmed: 9208980
WHO multicentre growth reference study group. WHO child growth standards based on length/height, weight, and age. Acta Paediatr. 2006;450:76–85.
doi: 10.1111/j.1651-2227.2006.tb02378.x
Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazancıoğlu R, Lamb E. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684–701.
doi: 10.1016/j.kint.2023.10.016 pubmed: 38519239
Greenbaum LA. Anemia in chronic renal disease. In: Geary DF, Schaefer F, editors. Pediatric kidney disease. Cham: Springer; 2023. pp. 1603–30.
doi: 10.1007/978-3-031-11665-0_59
Cohen CT, Powers JM. Intravenous iron therapy in pediatrics: who should get it and when is the right time? Hematol Am Soc Hematol Educ Program. 2023;2023(1):630–5.
doi: 10.1182/hematology.2023000496
McMurray J, Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J, Drüeke TB, Finkelstein FO, Fishbane S, Ganz T, MacDougall IC, Kidney Disease: Improving Global Outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.
Jabbar HK, Hassan MK, Al-Naama LM. Hematology, Transfusion and Cell Therapy. 2022.
Total iron measurement. In human serum with a novel smartphone-based assay. IEEE J Transl Eng Health Med. 2020;8:1–9.
Tilva SH, UR P, Goswami HM. Reticulocyte Hemoglobin Content (CHr): A Reliable Indicator in Iron Deficiency Anemia.
Irenge LM, Robert A, Gala JL. Quantitative assessment of human β-globin gene expression in vitro by TaqMan real-time reverse transcription-PCR: comparison with competitive reverse transcription-PCR and application to mutations or deletions in noncoding regions. Clin Chem. 2005;51(12):2395–6.
doi: 10.1373/clinchem.2005.056630 pubmed: 16306108
Bamgbola OF, Kaskel FJ, Coco M. Analyses of age, gender, and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol. 2009;24:571–9.
doi: 10.1007/s00467-008-0954-3 pubmed: 18800231
Elalfy MS, Aloraby MF, Elshimy A, Sallam DE. Iron status in chronic kidney Disease Pediatric patients on Hemodialysis. GEGET. 2023;18(1):43–56.
doi: 10.21608/geget.2023.308023
Kadatane SP, Satariano M, Massey M, Mongan K, Raina R. The role of inflammation in CKD. Cells. 2023;12(12):1581.
doi: 10.3390/cells12121581 pubmed: 37371050 pmcid: 10296717
Ryan AM, Cushen S, Bhuachalla EN, Dwyer F, Power DG. The role of inflammatory biomarkers in the Assessment of Nutritional Status and Disease States. Top Clin Nutr. 2015;30(1):3–15.
doi: 10.1097/TIN.0000000000000016
Dinh NH, CheanhBeaupha SM, Tran LT. The validity of reticulocyte hemoglobin content and percentage of hypochromic red blood cells for screening iron-deficiency anemia among patients with end-stage renal disease: a retrospective analysis. BMC Nephrol. 2020;21:1.
doi: 10.1186/s12882-020-01796-8
Almashjary MN. Reticulocyte hemoglobin content: advancing the frontiers in Iron-deficiency Anemia diagnosis and management. J Appl Hematol. 2024;15(1):1–8.
doi: 10.4103/joah.joah_103_23
Badr MA, Elashkar SS, Ismail WA, Abozid AA, Hanna D. Role of reticulocyte hemoglobin content in diagnosis of iron deficiency anemia. Alex J Pediatr. 2023;36(2):105–12.
doi: 10.4103/ajop.ajop_24_23
Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, et al. The role of iron status markers in predicting response to intravenous iron in hemodialysis patients on maintenance erythropoietin. Nephrol Dial Transpl. 2001;16(7):1416–23.
doi: 10.1093/ndt/16.7.1416
Mehta S, Goyal L, Kaushik D, Gulati S, Sharma N, Harshvardhan L, Gupta N. Reticulocyte hemoglobin vis-a-vis immature reticulocyte fraction, as the earliest indicator of response to therapy in iron deficiency anemia. J Assoc Physicians India. 2017;65(12):14–7.
pubmed: 31556266
Ferrer M, Ortega O, Colomina J, Mulet C, Martínez A, Esteban MJ, Soriano JB. Reticulocyte parameters as early markers of response to recombinant human erythropoietin in children with chronic renal failure. Nefrología. 2018;38(1):89–94. https://doi.org/10.1016/j.nefro.2017.06.007 .
doi: 10.1016/j.nefro.2017.06.007
Badura K, Janc J, Wąsik J, Gnitecki S, Skwira S, Młynarska E, Rysz J, Franczyk B. Anemia of chronic kidney Disease—A narrative review of its pathophysiology, diagnosis, and management. Biomedicines. 2024;12(6):1191.
doi: 10.3390/biomedicines12061191 pubmed: 38927397 pmcid: 11200696

Auteurs

Abier Abdelaziz Makkawi Abdelrahman (AAM)

Department of Haematology, College of Graduate Studies and Scientific Research, Karary University, Khartoum, Sudan. aberahmam@gmail.com.

Ahmed Ibrahim Marzouk (AI)

Delta Scientific Consultation Center Alexendria, Alexandria, Egypt.

Osama Ali Altayeb (OA)

Flowcytometry Laboratory, Khartoum, Sudan.

Eman Abbas Fadul (EA)

Flowcytometry Laboratory, Khartoum, Sudan.

Mugtaba Osman (M)

Umm Salal Treatment and Rehabilitation Centre, Department of Psychiatry, Hamad Medical Corporation, Doha, Qatar.

Nahla Allam (N)

Department of Pediatrics, Faculty of Medicine, Al Neelain University, Khartoum, Sudan.
Noura Center for Pediatric Kidney Disease and Kidney Transplant, Soba University Hospital, Khartoum, Sudan.

Nadia Madani Mohammed Ahmed (NMM)

Department of Haematology, Faculty of Medical Laboratories, Karrary University, Khartoum, Sudan.

Nazik Elmalaika Obaid Seid Ahmed Husain (NEOSA)

Department of Pathology, Faculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH